uniQure (NASDAQ:QURE) Short Interest Up 22.8% in July

uniQure (NASDAQ:QURE) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 3,180,000 shares, a growth of 22.8% from the June 30th total of 2,590,000 shares. Based on an average daily volume of 2,730,000 shares, the days-to-cover ratio is currently 1.2 days.

uniQure Price Performance

QURE traded up $0.11 during trading hours on Tuesday, hitting $7.91. The company’s stock had a trading volume of 166,410 shares, compared to its average volume of 1,770,116. The company has a current ratio of 9.39, a quick ratio of 9.27 and a debt-to-equity ratio of 0.70. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The stock has a market cap of $384.03 million, a price-to-earnings ratio of -1.26 and a beta of 0.97. The business’s 50-day moving average price is $5.81 and its 200-day moving average price is $5.49.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The business had revenue of $8.49 million for the quarter, compared to the consensus estimate of $2.58 million. uniQure had a negative return on equity of 121.60% and a negative net margin of 1,562.22%. Sell-side analysts expect that uniQure will post -4.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in QURE. Raymond James & Associates raised its holdings in uniQure by 6.4% in the 4th quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 3,145 shares during the period. China Universal Asset Management Co. Ltd. raised its position in uniQure by 58.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 3,664 shares in the last quarter. Pale Fire Capital SE raised its position in uniQure by 9.2% in the fourth quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after acquiring an additional 5,500 shares in the last quarter. Clear Harbor Asset Management LLC increased its position in shares of uniQure by 35.2% in the second quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 12,500 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of uniQure during the fourth quarter valued at $86,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

QURE has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 target price on shares of uniQure in a report on Tuesday, July 16th. Mizuho decreased their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.50.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.